Candance sells MACK 8.99: The Company is engaged in discovering, developing and preparing to commercialize medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer.

Sullivan sold 15,000 shares of the stock in a transaction dated Wednesday, July 15th. Nielsen sold 20,000 shares of the stock in a transaction dated Monday, July 20th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Guggenheim initiated coverage on Merrimack Pharmaceuticals in a research report on Wednesday, May 13th. MACK has been the topic of a number of recent research reports.


Kellee:
Merrimack Pharmaceuticals (NASDAQ:MACK) last posted its quarterly earnings data on Thursday, May 7th.

Nubia:
Analysts expect the company to announce earnings of ($0.31) per share and revenue of $17.57 million for the quarter.

Masako:
However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

Gilma:
Al-Wakeel continues Merrimack's expansion of its leadership team over the past several months to prepare for the transition into a commercial entity.  Birgit Schoeberl, PhD, was named Merrimack's head of Discovery.

Youlanda:
Before joining Credit Suisse, Dr.

Mitzie:
Al-Wakeel was one of Credit Suisse's top ranking research analysts covering the biotechnology and specialty pharmaceuticals sectors.  In total, Dr.

Chante:
Al-Wakeel joins Merrimack from Credit Suisse where he focused on biotechnology as a Director on the healthcare investment banking team.  Prior to that role, Dr.

Lonnie:
Merrimack Pharmaceuticals Names Dr.

Geraldine:
Merrimack anticipates that subsequent events and developments will cause its views to change.

Phyllis:
Merrimack has a New Drug Application under review for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK)
//stockhand.net/us/?q=nasdaq%3Amack&id=193884